HIV/AIDS

Latest News

Administration Delaying Approval of Life-Saving HIV Drugs

A new analysis by Rep. Waxman reveals that despite its public promises of quick action, the Administration is unnecessarily delaying the rapid approval of combination HIV therapies for use in Africa and other developing regions.

GlaxoSmithKline Withdrawal Undermines HIV Research in Africa

Rep. Waxman urges the pharmaceutical manufacturer to reconsider its decision to withdraw from a major NIH-sponsored HIV clinical trial, an action that is undermining efforts to determine how to treat millions of people infected with HIV around the world.

HHS Experts: Funding Increase Urgently Needed for HIV/AIDS Drug Program

In a letter to HHS, Democratic Leader Pelosi, Democratic Whip Hoyer, Rep. Waxman, Rep. Frank, Rep. Sherrod Brown, Del. Christensen, Rep. Lee and Rep. Baldwin make Secretary Thompson aware of his own agency's conclusion that an HIV/AIDS drug program for Americans lacking adequate health insurance urgently needs significantly more funding.

NIH Asked to Review Syringe Exchange Program as HIV Reduction Measure

Rep. Waxman and Rep. Cummings ask NIH Director Zerhouni to review the evidence on syringe exchange programs and other harm reduction measures to reduce the spread of HIV and other bloodborne diseases. UPDATE -- On Oct. 7, 2004, Dr. Zerhouni sent a response indicating that these measures “can be an effective public health approach” to reduce infectious disease transmission.

Administration Urged To Drop Roadblocks to Low-Cost, Effective HIV Combination Therapies

In a letter to the President, Rep. Waxman details Administration actions that have unnecessarily delayed and complicated the delivery of highly recommended, life-saving HIV therapies to developing regions.

Additional Federal Funding for HIV/AIDS Drug Program Urgently Needed

In a letter to HHS, Democratic Leader Pelosi, Democratic Whip Hoyer, Rep. Waxman, Rep. Frank, Rep. Sherrod Brown, Del. Christensen, Rep. Lee and Rep. Baldwin again write Secretary Thompson to emphasize the urgent need for additional federal funding for an HIV/AIDS drug program for Americans lacking adequate health insurance.

Administration Impeding Access to Life-Saving HIV Therapies in Africa, Other Developing Regions

Rep. Waxman objects to proposed drug approval standards, being circulated by the Administration for consideration at a conference next week in Botswana, that could block the use of the low-cost drugs needed to save the lives of millions of people living with HIV in Africa and other developing regions.

Budget Asks for Fraction of Needed AIDS Funding Increase

Eight members call on the Administration to ensure that a new CDC initiative will not leave thousands of Americans with an HIV diagnosis but without access to life saving drugs.

HHS May Use Audits to Harass Safe-Sex Groups

Rep. Waxman expresses continuing concern that HHS may be using audits to penalize groups who do not adhere to the Administration's abstinence-only approach to sex education.

New Policy Requires Additional Layer of Review for HIV/AIDS Prevention Efforts

In a letter to HHS Secretary Thompson, Democratic Leader Pelosi, Democratic Whip Hoyer, and Rep. Waxman urge the Secretary to reconsider a new CDC policy that requires HIV/AIDS prevention efforts to undergo an additional layer of review prior to distribution, changes which threaten to increase the burden on state and local health departments at a time when public health budgets are strained.

President Urged to Reverse Decision to Fund Anthrax Vaccine with Resources Devoted to HIV/AIDS, Other Health Threats

Senator Bingaman and Rep. Waxman urge President Bush to reverse the decision to fund the development of a new anthrax vaccine by robbing funds currently devoted to finding cures for HIV/AIDS, West Nile Virus, SARS, and other serious public health threats.

Administration Urged to Take Evidence-Based Approach to HIV/AIDS Prevention

Democratic Leader Pelosi and Rep. Waxman urge the Administration to take an evidence-based approach in their new HIV/AIDS prevention strategy and not be influenced by those who may be trying to politicize science and public health policy.

Displaying Items 26 to 37 of 37:

Previous Page • Next Page

[1] • [2]